I had a patient last month who had done everything right.

Sixty pounds down on tirzepatide over fourteen months. A1c from 6.4 to 5.3. Triglycerides cut in half. She told me she felt like a different person. Then she paused and said something I've heard many times before: "I'm scared my body is just waiting to take it all back."

I told her what I usually tell patients in that moment — that her physiology had genuinely changed, that staying on therapy was about maintaining a state, not earning one. All of that is true. But there's a part of the story I've been more careful about saying out loud, because until recently the data was thin.

Her cells remember. They will remember for years. And in the last eighteen months, the field has produced a remarkable convergence of evidence — across fat, immune cells, brain, and skin — explaining how that memory is written, how long it persists, and now, for the first time, how it might be interrupted.

That’s 6 sales in 7 months. 29 all time. And the performance?

16.5%, 17.6%, and 17.8%, net annualized returns on sold works held longer than one year (See all 29 at Masterworks.com)

It’s not from stocks, private equity, or real estate… it’s from contemporary and post war art. Crazy, right?

With Masterworks, you don’t need to be a BILLIONAIRE to invest in multi-million dollar art anymore.

Historically, the segment overall has had attractive appreciation and low correlation to stocks.*

Masterworks targets works featuring legends like Banksy, Basquiat, and Picasso, identifying what they believe to have significant long-term appreciation potential, not just at the artist level but at the level of individual artworks.

As one of the largest players in the art market, with $1.3 billion invested over 500 artworks, they pass critical advantages through to their 70,000+ members to add art to their portfolios strategically.

Looking to diversify your investments in 2026?

Click here to skip the waitlist

^{*According to Masterworks data. Investing involves risk. Past performance is not indicative of future returns. See important Reg A disclosures at masterworks.com/cd.}

For decades, obesity medicine has carried a quiet embarrassment. We could describe weight regain in elaborate detail — the ghrelin rebound, the leptin crash, the metabolic adaptation — but we couldn't really say why the body defended a higher set point so aggressively. We could measure the consequences of obesity memory without identifying the substrate that stored it.

The hormonal explanations told us what the body was doing but not what it was remembering. And they couldn't account for the consistency of the regain pattern — the same trajectory whether weight was lost via diet, surgery, or pharmacotherapy. Something more durable than circulating hormones had to be holding the memory in place.

The candidate that kept coming up was the epigenome: methylation patterns, histone modifications, and chromatin accessibility — chemical marks that don't change the genetic code but change which parts of it get read. If obesity left epigenetic scars on the most-affected cells, those scars would persist long after the weight came off. They would be the substrate of memory.

Between November 2024 and the first half of 2026, that hypothesis went from speculation to consensus. The field has even coined a term for it: biological hysteresis — the idea that the body, like a hysteretic physical system, doesn't trace the same path on the way down that it traced on the way up.

Laura Hinte and colleagues at ETH Zurich asked a deceptively simple question: if you take adipose tissue from someone two years after dramatic weight loss, does it look like adipose tissue from someone who never had obesity?

Using single-nucleus RNA sequencing, they sampled subcutaneous and omental adipose biopsies from individuals who had lost more than 25% of their BMI through bariatric surgery, and compared them to lean controls who had never carried obesity. Even after substantial, sustained weight loss, adipocytes from people with a history of obesity retained transcriptional fingerprints that distinguished them from those of lean controls. Key metabolic genes — IGF1, LPIN1, IDH1, PDE3A — remained suppressed. Pathways linked to fibrosis and apoptosis remained elevated. The cells had not gone back to baseline.

The mouse data went further. Hinte's group profiled four chromatin marks alongside chromatin accessibility, and showed that the persistent transcriptional changes weren't lingering hormonal echoes — they were anchored to stable epigenetic alterations. Between 57 and 75 percent of the persistent gene expression changes after weight loss were explained by one or more of these epigenetic modalities.

When they re-fed the mice with a history of obesity a high-fat diet, those mice gained weight faster than mice with no prior obesity history. Their adipocytes were also more efficient at absorbing nutrients. The memory wasn't just present — it was functional. It primed the system for relapse. For the first time, we had molecular evidence that adipose tissue carries its own historical record, and the record is written on chromatin.

Published last month, the Niven paper extends the story into a tissue compartment most clinicians don't think about: the adaptive immune system.

The Birmingham-led group built a parallel mouse model — chow diet, high-fat diet, and a recovery group that ate high-fat for eight weeks then chow for six. After fourteen weeks, the recovery mice looked metabolically normal. Their abdominal fat had shrunk back to baseline. But when they immunized those mice and looked at the resulting CD4 T cell response, the recovery group still resembled the obesity group, not the lean controls. The expansion of pro-inflammatory effector memory T cells — the workhorses of chronic inflammation — was indistinguishable from an animal with obesity. The immune system hadn't reset.

Only at the twenty-week time point — with twelve weeks of chow diet after eight weeks of high-fat — did the T cell phenotype begin to normalize. Translated into human time, the authors estimate this corresponds to roughly five to ten years of sustained weight maintenance.

Then they turned to humans. Three cohorts. None of them showed what we'd hope to see.

The pattern is clean and uncomfortable: weight loss alone, exercise alone, and even pharmacotherapy-induced weight loss across six months don't reach the cellular memory. The phenotype is durable. It outlasts the visible disease.

What makes the cellular memory story powerful isn't any single paper. It's that the same pattern is showing up wherever investigators choose to look.

In the brain, Hata and colleagues showed in Science in 2023 that a past period of diet-induced obesity in mice — even after the obesity was resolved and metabolism normalized — left persistent chromatin changes in microglia and macrophages, amplifying neuroinflammatory responses in a model relevant to age-related macular degeneration.

In adipose tissue macrophages, Caslin and colleagues at Vanderbilt demonstrated that weight loss following obesity primed macrophages for more inflammation, not less, upon weight regain. On second exposure, they responded faster and harder.

In skin, a 2026 paper by Kamada and colleagues showed that high-fat-diet-induced obesity altered cutaneous immune cell function — and that those changes persisted after weight loss. A tissue compartment no one had thought to interrogate displayed the same pattern.

A May 2026 Obesity Reviews paper by Corrao and colleagues used AI-driven semantic mapping to formalize what's emerging across these studies. Their term — biological hysteresis — captures something physicists have known for centuries: a system pushed into a new state often refuses to return cleanly to where it started, even when the original force is removed. The body, in this framing, isn't broken. It's behaving exactly like a hysteretic system.

The mechanistic part of the Niven paper is where it earns its keep, because it doesn't just describe the phenomenon — it locates a biophysical pathway.

Using reduced-representation bisulfite sequencing, the group identified 104 genes with altered methylation in T cells from obese and recovery mice versus lean controls. Seventy were hypomethylated — primed for increased expression. Two stood out:

STK26, a kinase that drives autophagy. In obesity-experienced T cells, the gene is demethylated, expression rises, and autophagy flux increases. Knocking out STK26 in mice blunted the inflammatory T cell expansion that normally follows a high-fat diet. Autophagy here isn't just housekeeping — it's a permissive substrate for the inflammatory memory phenotype.

CDKN1C, a cyclin-dependent kinase inhibitor that drives cellular senescence. Senescent immune cells secrete the senescence-associated secretory phenotype (SASP), perpetuating the very inflammation they emerged from. Senescence-marked TEMRA cells were elevated in Alström syndrome patients and persisted after semaglutide-induced weight loss.

The most provocative piece is the how. Saturated fatty acids — particularly palmitate — alter the biophysical properties of the cell membrane itself. Using a polarity-sensitive dye, the authors showed that palmitate increases lipid packing and membrane order. Disrupting membrane microdomains with methyl-β-cyclodextrin reversed both the ordering effect and the methylation changes at STK26. The signal travels from the lipid bilayer to the nucleus.

When a T cell sits in a milieu of saturated fat for long enough, the physics of its outer membrane change, signal transduction is reshaped, and stable methylation marks get laid down at genes governing autophagy and senescence. The cell carries that methylation pattern forward across divisions. The memory is chemical and inheritable, not transient.

All of this would be intellectually interesting but clinically irrelevant if patients didn't actually behave the way the cellular biology predicts. In November 2025, we got a clean test.

Horn and colleagues published a post-hoc analysis of SURMOUNT-4 in JAMA Internal Medicine. Adults with obesity took tirzepatide for 36 weeks, then were randomized to continue or switch to placebo for 52 weeks. The post-hoc asked what happened to those who stopped.

82.5% of patients who discontinued tirzepatide regained at least 25% of their lost weight within one year. And the regain wasn't just on the scale — it dragged cardiometabolic parameters with it. Waist circumference, non-HDL cholesterol, fasting insulin, blood pressure, and glycemic markers all moved in proportion to how much weight came back. The patients who regained the most also lost the most of their cardiovascular and metabolic improvements.

This is what cellular memory looks like in a clinic visit. The patient who comes back six or twelve months after stopping their GLP-1, weight nearly back to baseline, A1c climbing again, blood pressure no longer well-controlled — that patient is not a treatment failure. They are the predictable output of a system in which adipocytes are still suppressing IGF1, T cells are still primed for inflammation, macrophages are still set up to overreact, and an obesogenic environment is still talking to all of them.

SURMOUNT-4 paired with the cellular biology lands at a single conclusion: stopping the medication doesn't end the disease. It just removes the only thing currently keeping the disease quiet.

Until very recently, the takeaway was sobering: the cells remember, we can't yet make them forget, and the only available strategy is to keep the obesogenic environment turned down — which in 2026 means staying on therapy.

A January 2025 preprint by Jamie Garcia and Alyssa Hasty's group at Vanderbilt is the first paper I've seen that genuinely cracks that wall. They reasoned that if memory T cells are part of the regain-amplifying machinery, then interrupting the molecular handshake that creates those memory cells might blunt the consequences of weight cycling. Their target was the CD70–CD27 axis — a co-stimulatory pair critical for memory T-cell formation.

In CD70-knockout mice, the result was clean. Memory T cells in adipose tissue after weight cycling were reduced. T-cell clonality dropped. And while the knockout mice did just as well as wild-type mice during stable obesity, they were protected from the worsened glucose intolerance that wild-type mice developed during weight cycling. The mice that couldn't form a robust immune memory of obesity didn't pay the metabolic tax that comes with weight cycling.

This is preclinical work in a single model, and CD70/CD27 blockade in humans carries immunologic implications well beyond obesity medicine. But it is the first proof that the cellular memory of obesity is not a fixed feature of biology. It is a target. Something has to instruct those memory T cells into existence, and if you interrupt that instruction, the memory is incomplete — and the downstream metabolic damage is reduced.

Three things shift when you take this biology seriously.

First, the timeline of treatment. If cellular memory takes years to fade, then duration of obesity pharmacotherapy stops being a question of compliance and becomes a question of biology. SURMOUNT-4 and the STEP 1 extension weren't showing drug failure — they were showing what the underlying disease does when you remove its only restraint. Maintenance trials like SURMOUNT-MAINTAIN, ask exactly the right next question: how little of the drug is needed to hold the line while the cells slowly reprogram.

Second, the framing of weight regain. The dominant cultural narrative is still moral: they got complacent, they lost discipline. The cellular data demolish that frame. Weight regain is the predictable behavior of a system whose adipocytes and immune cells are still operating from an obesogenic playbook, written in methylation marks the patient never agreed to and cannot undo by trying harder.

Third, the rationale for combination therapy. If autophagy, senescence, and memory T-cell formation are causally involved, drugs targeting those pathways become candidates for accelerating the return to homeostasis. The Niven authors flag SGLT2 inhibitors, citing 2024 work from Katsuumi showing canagliflozin can promote immune-mediated clearance of senescent cells in obesity. The Garcia paper opens a separate door at CD70–CD27. We are nowhere near a clinical trial of GLP-1 plus senolytic or GLP-1 plus immune-memory blockade. But the mechanistic case is articulated, the preclinical proof-of-concept exists, and it would be surprising if these combinations didn't get tested in the next five years.

When I told my patient her body was holding the disease in its cells, I wasn't being poetic. I was describing a methylation pattern at STK26, a chromatin state in her adipocytes, a TEMRA population in her peripheral blood, a primed macrophage compartment in her abdominal fat — and, based on what 82.5% of SURMOUNT-4 patients did, a system that would almost certainly try to undo most of what she'd accomplished if we removed her only restraint.

None of that is her fault. None is fixed by trying harder. It is fixed — slowly, over years — by sustained maintenance of the weight-reduced state, which for most people now means staying on therapy. That's not a moral statement about willpower. It's an honest reading of what the cells are doing.

Six papers, four cell types, one clinical trial showing the whole biology playing out in real patients, and the first crack in the wall from a preclinical model showing the memory can be interrupted. The body keeps a record. We know how it's written. We're starting to know how long it takes to fade. And we're starting — just starting — to see how it might one day be erased. That alone changes the conversation we owe our patients.

REFERENCES

Niven J, Kucuk S, Gope A, et al. DNA methylation-mediated memory of obesity in CD4 T lymphocytes perpetuates immune dysregulation. EMBO Reports. 2026. doi: 10.1038/s44319-026-00765-w. Published online April 27, 2026.

Hinte LC, Castellano-Castillo D, Ghosh A, et al. Adipose tissue retains an epigenetic memory of obesity after weight loss. Nature. 2024;636(8042):457–465. doi: 10.1038/s41586-024-08165-7.

Hinte LC, Castellano-Castillo D, von Meyenn F. Long-term impact of obesity: Unraveling adipose epigenetic memory. Clin Transl Med. 2025;15(3):e70254. doi: 10.1002/ctm2.70254.

Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. Published online November 24, 2025. doi: 10.1001/jamainternmed.2025.6112.

Garcia JN, Cottam MA, Rodriguez AS, Hussein Agha AF, Winn NC, Hasty AH. Interrupting T-cell memory ameliorates exaggerated metabolic response to weight cycling. bioRxiv. 2025;633599. doi: 10.1101/2025.01.17.633599. (Indexed via PubMed 2026.)

Corrao S, Tuccinardi D, Baratta R. Beyond Weight Loss: Obesogenic Memory as Biological Hysteresis in Adipose Tissue Revealed by AI Semantic Mapping With an Exportable Core Corpus. Obes Rev. 2026;e70155. doi: 10.1111/obr.70155.

Hata M, Andriessen EMMA, Hata M, et al. Past history of obesity triggers persistent epigenetic changes in innate immunity and exacerbates neuroinflammation. Science. 2023;379(6627):45–62. doi: 10.1126/science.abj8894.

Caslin HL, Cottam MA, Piñon JM, Boney LY, Hasty AH. Weight cycling induces innate immune memory in adipose tissue macrophages. Front Immunol. 2023;13:984859. doi: 10.3389/fimmu.2022.984859.

Kamada W, Tanno H, Takayashiki R, et al. High Fat Diet-Induced Obesity Alters Cutaneous Immune Cell Function, and These Changes Persist After Weight Loss. J Immunol Res. 2026;2026:3930910. doi: 10.1155/jimr/3930910.

Mauro C, Smith J, Cucchi D, et al. Obesity-induced metabolic stress leads to biased effector memory CD4+ T cell differentiation via PI3K p110δ-Akt-mediated signals. Cell Metab. 2017;25(3):593–609.

Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.

Katsuumi G, Shimizu I, Suda M, et al. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nat Aging. 2024;4(7):926–938.